Skye Bioscience (SKYE)

• Market cap: $111M
• 1 day: 1.13%
• 5 days: 6.23%
• 1 month: -4.28%
• 3 months: 62.73%
• 6 months: 28.78%
• Year to date: 25.61%
• 1 year: -47.81%
• 5 years: -71.79%
• 10 years: -71.79%
• Sector: Healthcare
• Industry: Biotechnology

About: Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Employees: 16

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

160% more call options, than puts

Call options by funds: $224K | Put options by funds: $86K

116% more capital invested

Capital invested by funds: $39.3M [Q1] → $85M (+$45.7M) [Q2]

14.11% less ownership

Funds ownership: 79.73% [Q1] → 65.62% (-14.11%) [Q2]

25% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 16

25% less funds holding

Funds holding: 75 [Q1] → 56 (-19) [Q2]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]

57% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 28

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $10 179% upside
• Avg. target: $12.50 249% upside
• High target: $15 319% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Evercore ISI Group Michael DiFiore	179% upside $10	Outperform Initiated	15 Aug 2025
JMP Securities Jonathan Wolleben	319% upside $15	Market Outperform Reiterated	24 Jun 2025